Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ARIAD Pharmaceuticals, Inc.
ARIAD Reports Second Quarter 2008 Financial Results
August 23rd, 2008
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) reported financial results for the second quarter and six months ended June 30, 2008, provided an update on corporate developments and announced changes in its senior management team. "In the second quarter of 2008, we made important progress in expanding and advancing our clinical programs, and we are executing well in all areas of our business," stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "Our partnership with Merck & Co., Inc. for the global development of our investigational mTOR inhibitor, deforolimus, is strong and productive, and we remain focused on delivering results consistent with...
Source: Law & Health Weekly (2008-08-23)
|
